Judicial biomarker accountability doctrine

Introduction

The Judicial biomarker accountability doctrine may be understood as a developing legal framework concerning the responsibility of courts, regulatory authorities, medical professionals, laboratories, researchers, and biotechnology companies for the use, interpretation, disclosure, and evidentiary treatment of biomarkers in judicial and clinical decision-making. A biomarker is a measurable biological characteristic that can indicate a physiological or pathological process, disease state, treatment response, or biological risk. Examples include genetic variants, proteins, circulating tumour DNA, hormone levels, imaging indicators, and molecular signatures.

The doctrine becomes particularly important where biomarker evidence is used to determine medical eligibility, causation, liability, criminal responsibility, discrimination, patent disputes, or regulatory compliance. Courts must determine not merely whether a biomarker exists, but whether it has sufficient scientific validity and reliability to support a legal conclusion.

Scientific reliability and judicial responsibility

Courts increasingly encounter technically complex scientific evidence. Biomarker evidence can appear highly objective because it is expressed through laboratory measurements or statistical results. However, scientific precision does not automatically establish legal reliability.

A court should consider whether the biomarker has been adequately validated, whether the testing methodology is reliable, whether relevant reference populations have been considered, and whether the evidence establishes correlation or actual causation.

This distinction is crucial. A biomarker may correlate with a disease without proving that the biomarker caused the disease. Similarly, a genetic variant may be associated with an increased probability of developing a condition without establishing that the individual will necessarily develop it.

Judicial accountability therefore requires courts to avoid treating biomarker evidence as scientifically conclusive merely because it is presented in technical or numerical form.

Biomarker evidence and causation

In civil litigation, biomarkers may be used to establish exposure, injury, disease progression, or treatment effects. The court must distinguish between evidence demonstrating biological association and evidence satisfying the applicable legal standard of causation.

For example, the presence of a molecular marker may establish that a particular biological process occurred, but additional evidence may be required to demonstrate that a defendant's conduct caused that process.

Courts should therefore evaluate biomarker evidence together with epidemiological, clinical, laboratory, and factual evidence.

Genetic biomarkers and discrimination

Genetic biomarkers create additional legal concerns because genetic information can affect not only the individual but also biological relatives.

A genetic biomarker indicating susceptibility to cancer, cardiovascular disease, or another condition could potentially be misused by employers, insurers, financial institutions, or other organizations.

A judicial accountability framework should therefore incorporate privacy, equality, proportionality, and anti-discrimination principles. Courts should be cautious about permitting predictive genetic information to become the basis for decisions that are not scientifically or legally justified.

Biomarkers in criminal proceedings

Biomarkers can potentially become relevant in criminal investigations through DNA analysis, toxicology, neurological evidence, or other biological indicators.

DNA evidence has particular importance because it may establish identity or biological relationships with considerable evidentiary strength. Nevertheless, courts must consider chain of custody, laboratory methodology, contamination, statistical interpretation, and the distinction between a DNA match and proof of guilt.

Biomarker evidence should not be presented as determinative of guilt where it merely establishes a biological association with a person or location.

Relevant case laws

Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993): The U.S. Supreme Court established important principles concerning the admissibility of expert scientific evidence. Courts should consider factors such as testability, peer review, known or potential error rates, standards controlling the technique, and general acceptance. These principles are highly relevant when courts evaluate novel biomarker technologies.

General Electric Co. v. Joiner, 522 U.S. 136 (1997): The Supreme Court emphasized that courts may examine the analytical connection between scientific evidence and the conclusion offered by an expert. The case is important where biomarker evidence is scientifically valid in isolation but does not logically establish the particular conclusion asserted in litigation.

Kumho Tire Co. v. Carmichael, 526 U.S. 137 (1999): The Court extended the gatekeeping responsibility concerning expert evidence beyond strictly scientific testimony. The reasoning supports careful judicial scrutiny of specialized technical evidence, including complex laboratory and biomarker methodologies.

Snyder v. Louisiana? Not appropriate biomarker. Better DNA cases.

Maryland v. King, 569 U.S. 435 (2013): The U.S. Supreme Court considered collection and analysis of DNA from individuals arrested for serious offenses. The case demonstrates the constitutional and privacy dimensions of biological identification systems.

District Attorney's Office for the Third Judicial District v. Osborne, 557 U.S. 52 (2009): The Supreme Court considered post-conviction access to DNA testing. The case illustrates the significance of reliable biological evidence in criminal justice and the legal limitations surrounding access to testing.

Biomarker evidence and medical negligence

Biomarkers can also become important in medical-malpractice litigation. A laboratory may be accused of failing to detect a clinically significant biomarker, incorrectly interpreting a result, or reporting an inaccurate result.

Liability may depend upon whether the laboratory followed accepted professional standards, whether the testing method was appropriate, whether the result was reasonably interpretable at the relevant time, and whether the error caused legally recognizable harm.

The existence of a biomarker alone does not necessarily establish negligence. Courts must examine the state of scientific knowledge when the test was performed.

Biomarker interpretation and changing science

Scientific knowledge develops rapidly. A biomarker classified as uncertain today may later become clinically significant, while an apparently important marker may subsequently be shown to have limited predictive value.

Judicial accountability should therefore avoid evaluating historical scientific conduct exclusively through current knowledge. The relevant question is ordinarily whether the defendant's conduct was reasonable according to the applicable scientific and professional standards at the relevant time.

This principle is particularly important in genomics and precision medicine.

Privacy and biomarker information

Biomarker information can constitute highly sensitive personal information. Genomic biomarkers may reveal information about disease susceptibility, ancestry, biological relationships, and potential future health conditions.

S. and Marper v. United Kingdom (ECtHR, 2008) is relevant because the European Court of Human Rights recognized significant privacy concerns associated with retaining DNA profiles and other biological information.

In India, Justice K.S. Puttaswamy (Retd.) v. Union of India (2017) recognized privacy as a fundamental right under Article 21 of the Constitution. The judgment provides a strong constitutional foundation for protecting sensitive health and genetic information.

Regulatory accountability

Biomarker accountability also extends to regulatory authorities approving diagnostic tests and biomarker-based medical products. Regulators must ensure that claims concerning analytical validity, clinical validity, and clinical utility are supported by appropriate evidence.

A diagnostic company should not present a biomarker as capable of predicting disease or treatment response unless the evidence supports the relevant claim.

Regulatory decisions should also provide appropriate mechanisms for monitoring adverse events, correcting inaccurate information, and reassessing tests when scientific evidence changes.

Judicial standards for biomarker evidence

A coherent judicial doctrine could require courts to examine five principal factors:

1. Analytical validity — whether the test accurately measures the biomarker.
2. Clinical validity — whether the biomarker reliably relates to the relevant clinical condition.
3. Clinical utility — whether using the biomarker actually improves clinical decision-making.
4. Statistical reliability — whether the evidence has appropriate sensitivity, specificity, confidence intervals, and error analysis.
5. Legal relevance — whether the scientific evidence actually proves the legal proposition for which it is offered.

This prevents courts from confusing sophisticated scientific terminology with legally sufficient proof.

Conclusion

The Judicial biomarker accountability doctrine represents an emerging intersection of evidence law, biotechnology, medical law, privacy law, scientific methodology, and judicial responsibility. Its central principle is that biomarker evidence should be assessed according to its scientific reliability, limitations, context, and actual relevance to the legal issue before the court.

Cases such as Daubert, Joiner, Kumho Tire, Maryland v. King, and Osborne demonstrate the importance of scientific reliability, expert-evidence scrutiny, biological privacy, and dependable DNA evidence. Puttaswamy further provides an important Indian constitutional foundation for protecting sensitive health and genetic information.

Ultimately, courts should neither reject biomarker evidence merely because it is technologically complex nor accept it simply because it appears scientifically precise. Reliable methodology, validated evidence, transparent interpretation, appropriate statistical analysis, privacy protection, and careful judicial scrutiny should determine the legal weight assigned to biomarker evidence.